Abstract: A resource collision indication method includes that: a first device whether to send first information indicating that a resource collision is likely to occur on a resource to be used by a second device. A resource collision indication device and a computer readable storage medium are also provided.

Abstract: A resource determination method and device are provided. The method comprises: a terminal determines a time range of continuous partial listening; and on the basis of a listening result within the time range, the terminal performs resource exclusion on resources in a candidate slot corresponding to the time range.

Abstract: Disclosed are a resource reselection method and a terminal device. The method includes: determining target selected slots and target sensing slots by a terminal device; obtaining a candidate resource set by performing resource exclusion on candidate resources in the target selected slots according to non-monitored slots and/or sensing result in the target sensing slots; and in a case where it is determined to perform reselection for a first resource that has been selected by the terminal device, selecting a second resource from the candidate resource set for replacement of the first resource.

Abstract: An electric valve and an assembly method therefor. The provision of multilayered sealing of a first sealing element, a second sealing element, and a sealing medium located between the first sealing element and the second sealing element along the axial direction of a valve stem is conducive to restricting outward leakage of a fluid along the axial direction of the valve stem.

Abstract: A wireless communication method and a terminal device are provided. A first terminal device sends first information to a second terminal device, where the first information indicates that the second terminal device is to provide a first resource set, and the first resource set is used for the first terminal device to select a transmission resource.

Abstract: Provided in the embodiments of the present application are a wireless communication method and a device. The method comprises: a first terminal receiving sidelink data, which is sent by a second terminal on a plurality of carriers; and according to at least one of the following: the plurality of carriers, first indication information, carrier configuration information of a PSFCH, and a CBR, the first terminal selecting at least one carrier for transmitting the PSFCH.

Abstract: Provided in the present application are a resource selection method and apparatus for use in a sidelink communication system. The resource selection method includes: a first terminal receives sidelink data from a second terminal on a plurality of carriers; and the first terminal may select a resource pool for transmitting a PSFCH from the plurality of carriers where the sidelink data is located, or all the plurality of carriers available for sidelink transmission.

Abstract: Provided by the present invention is a mutant lysyl-tRNA synthetase that has a deletion mutation at one or more sites selected from the group corresponding to the amino acid sequence of wild-type aminoacyl-tRNA synthetase: 102nd, 128th-140th, and 159th-179th amino acid residues. Compared with wild-type lysyl-tRNA synthetase, the mutant lysyl-tRNA synthetase according to the present invention has high activity, a high level of expression and good solubility, and may significantly increase the amount of an inserted unnatural amino acid and the level of expression of a target protein containing an unnatural amino acid.

Abstract: Provided are a polypeptide derivative and a preparation method thereof. Specifically, a polypeptide derivative is provided. Experimental results show that the polypeptide derivative has a significantly prolonged half-life while maintaining biological activity. The preparation method of the polypeptide derivative and its use in therapy are also disclosed.

Abstract: Provided is a mutant lysyl-tRNA synthetase. Compared with a wild-type lysyl-tRNA synthetase, the mutant lysyl-tRNA synthetase of the present invention can increase the amount of non-natural amino acids inserted and the amount of a protein of interest containing non-natural amino acids, and can also improve the stability of the protein of interest, thereby making same less prone to fragmentation.

Abstract: Provided are a fusion protein containing fluorescent protein fragments and uses thereof. The fusion protein according to the present invention has a structure as expressed by (P1-L1)s-A1-(X)n-A2-(L2-P2)t, wherein (X)n or A1-(X)n can promote the folding and expression of fused target peptide, improve the solubility of the fusion peptide and reduce the interaction among fusion peptide molecules. (X)n or A1-(X)n in the fusion protein can be cut by enzymes into a plurality of short peptides with a length much shorter than that of the target peptide, which facilitates the separation from the target peptide so as to make the purification of the target peptide more convenient.

Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein W, X, Y, and R1-R7 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1—R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Abstract: The present invention provides compounds of formula or pharmaceutically acceptable salts, esters or stereoisomers thereof, wherein R1 to R4, A and Y have the meanings given herein, as well as methods for making those compounds and their use as medicament, in particular as medicament for the treatment of cancer.

Abstract: The present invention provides compounds of formula or pharmaceutically acceptable salts, esters or stereoisomers thereof, wherein R1 to R4, A and Y have the meanings given herein, as well as methods for making those compounds and their use as medicament, in particular as medicament for the treatment of cancer.

Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1-R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1-R5, A, B, Q, W, and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1-R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Abstract: Compounds of formula are HDAC inhibitors. These compounds are useful for the treatment of diseases such as cancer in humans or animals.

Abstract: Compounds of formula are HDAC inhibitors. These compounds are useful for the treatment of diseases such as cancer in humans or animals.